10x Genomics (TXG) Q1 2026 Earnings Transcript

10x Genomics reported Q1 revenue of $150.8 million, up 9% ex-settlement revenue, with consumables revenue up 13% and gross margin expanding to 70% from 68%. Management maintained full-year 2026 revenue guidance of $600 million to $625 million, but flagged sequential Q2/Q3 pressure as customers delay spatial purchases ahead of Atara, a major new platform launch. The company said early Atara demand is strong, with about 40 units expected to ship between Q3 and Q4, while cash rose to $540 million and OpEx fell 15% year over year.

Analysis

The market is still underestimating how much of TXG’s near-term tape is being pulled forward versus destroyed. The Q2/Q3 air pocket looks less like a demand collapse and more like customers waiting for a clearly superior platform, which means the key variable is conversion timing, not end-market size. That creates a classic setup where headline revenue can soften while forward backlog and mix quality improve, making the stock vulnerable to a reflexive selloff that may be larger than the underlying fundamental change.

The more interesting second-order effect is competitive displacement inside TXG’s own portfolio. Atara should expand the spatial TAM, but in the next 2-3 quarters it likely compresses revenue recognition from legacy spatial systems and can pressure gross margin exactly when investors will be trying to extrapolate the launch curve. That combination—lower instrument mix, delayed purchasing, and limited initial unit capacity—creates a valuation reset risk even if the long-duration thesis is intact.

On the upside, the AI/data partnerships are not just marketing; they are a lead-indicator for higher-throughput, cohort-oriented workflows that can re-rate the company from a tool vendor to an enabling infrastructure layer. The contrarian point is that consensus is probably too focused on cannibalization and not enough on installed-base expansion: if Atara becomes the standard for big translational and AI datasets, older platforms can still monetize the long tail while the new system opens a larger budget pool. The real catalyst window is 6-18 months, when preorder conversion, installation cadence, and 2027 budget planning determine whether this is a product-cycle trade or a multi-year platform step-up.

Key Decisions for Investors

• Go long TXG on post-print weakness, but only on a 3-6 month horizon; best entry is on any drawdown tied to Q2/Q3 revenue fears, with upside driven by preorder conversion and 2027 budget cycles rather than near-term earnings beats.
• Buy TXG Jan-2027 calls and fund partially by selling nearer-dated upside; this expresses the view that the market will overreact to the 2026 air pocket while underpricing the Atara ramp into 2027.
• Pair trade: long TXG / short a capital-equipment or life-science tools peer with similar valuation sensitivity to instrument cycles; the relative thesis is that TXG’s consumables base and data-platform narrative are stronger than a simple hardware launch story.
• Avoid chasing immediately after strength in the stock; if management is right, the better risk/reward comes after the first quarter of sequential weakness when sell-side models cut numbers before preorder data becomes visible.
• If TXG rerates on Atara enthusiasm, trim into strength above any valuation level that implies flawless execution; the margin-capex/mix risk makes this a better buy on skepticism than on momentum.